GenIP PLC Reports H1 2025 Results with Global Expansion and Strong Order Book

GenIP H1 2025: global reach widens while revenues lag delivery

GenIP PLC has published its half-year results to 30 June 2025 and issued a small “replacement” RNS to fix a formatting issue so the Statement of Financial Position displays correctly. The business story is intact: growing international traction, a bigger order book, and a lean first half on recognised revenue as projects stack up for delivery in H2.

If you’re new to the name, GenIP provides AI-enabled innovation evaluation and talent services for universities, corporates and government agencies. The plan is to shift from project-based consultancy towards a platform-led, recurring model with higher margins.

What changed in this replacement RNS

The only amendment relates to RNS formatting – the Statement of Financial Position is now visible. The PDF on the company’s site already showed it correctly. All other text and numbers are unchanged.

Key H1 2025 numbers investors need to know

Metric	H1 2025
Revenue	$125,166
Gross profit (margin)	$22,620 (18.1%)
Operating loss	$571,630
Loss before tax	$565,585
Cash and cash equivalents	$1,076,818
Operating cash flow	$241,951 inflow
Order book (30 June 2025)	$813k
Orders received in H1	$488k
Deferred revenue	$418,335
Net assets	$745,382

Currency: US dollars.

Commercial momentum: contracts, geographies and new products

GenIP is clearly landing bigger fish across more waters. Management says the company now has a footprint in 25 countries, backed by specific contract wins in H1:

• $350,000 order in Saudi Arabia for 400 AI-enhanced Invention Evaluator assessments plus commercialisation consulting – expected to be fulfilled this financial year.
• $65,000 order in Singapore for 100 AI-enabled assessments as part of expansion into Asia via technology transfer sponsorships – also expected to be fulfilled this year.
• First Brazilian contract with a government research funding agency for AI-enhanced technology evaluation in a national bio-energy initiative.
• 30 assessment orders in Chile from a leading research institution.
• Launched an AI-powered Competitive Intelligence Report, with a Big Four accountancy firm using it for strategic due diligence.

Post period, more building blocks dropped into place:

• First Australian client via a government-funded university-industry consortium spanning advanced telecommunications, IoT, satellites and Earth observation.
• Strategic partnership with 360 Social Impact Studios, embedding Invention Evaluator into their venture-building methodology.
• Appointed technology transfer provider to the GreenTech Innovation Platform in Chile with Universidad Autónoma de Chile.
• New “Invention Validator” line – market validation and buyer perception studies to test real-world adoption and pricing sensitivity.
• Hired a head of Innovation & Deep Tech Talent to scale recruitment services.

From consultancy to platform: why the model shift matters

The CEO frames this period as a structural pivot: using Invention Evaluator as the entry point, then layering higher-margin, repeatable services and progressing towards SaaS-style, dashboard-led delivery. The priorities are explicit:

• Deepen program-level partnerships to drive recurring revenues.
• Lift corporate client share from about 30% to around 45% in the medium term.
• Introduce client-led, higher-margin services and improve automation to support throughput and target gross margins above 60% over time.
• Leverage de-identified, aggregated portfolio data to refine AI models and strengthen decision support.

In short, GenIP wants to move from one-off reports to a platform and data moat. That is strategically sound if execution keeps pace.

Cash, liquidity and related-party housekeeping

Cash was $1,076,818 at 30 June 2025. The company generated $241,951 of operating cash inflow in H1, helped by pay-in-advance terms, which is reflected in deferred revenue of $418,335. There’s no other debt, and the convertible loan note with Tekcapital was offset and closed (effective 31 December 2024).

Other operating income of $100,000 stems from Tekcapital agreeing to contribute towards prior IT development costs – recognised over two years. Related-party costs also appear via Phosphorix Ltd (CTO-owned) for Invention Evaluator operations and development, and $8,000 of sales to Guident Limited. This is common in early-stage setups, but investors should keep an eye on disclosures and arm’s length pricing, as the company says it is.

Execution gap: revenue recognition trailing orders

The headline tension is straightforward. GenIP booked $488k of orders and reported an $813k order book by June, yet H1 revenue was only $125,166. Management says larger orders landed early in the year are scheduled for fulfilment by year end, so H2 should be “significantly” stronger.

The risk is timing: delivery and client acceptance need to convert swiftly to recognised revenue. The positive counterpoint is operating cash inflow and deferred revenue, both of which suggest customers have paid deposits and work is underway.

What looks positive

• Growing order book and prepayments – $813k order book and $418,335 deferred revenue support a stronger H2 delivery profile.
• International traction – Saudi Arabia, Singapore, Brazil and Chile contracts illustrate a replicable proposition across regions.
• Product broadening – Competitive Intelligence Report and Invention Validator create higher-margin upsell paths atop Invention Evaluator.
• Cash position – $1,076,818 provides flexibility to fulfil current orders and invest in growth, with no other debt.
• Cost discipline shift – share-based payments reduced to $62,068 in H1 (from $359k in 2024), reweighted towards marketing and team build-out.

What needs improvement

• Revenue scale – $125,166 of H1 revenue is small relative to the cost base.
• Gross margin – 18.1% is well below the stated ambition of 60%+. Margin expansion depends on automation, product mix, and platform delivery.
• Operating loss – $571,630 reflects early-stage investment. Repeatable, higher-margin workflows must start showing up in recognised revenue.
• Related-party exposure – present and disclosed; continue to watch governance and pricing as the business scales.

Outlook: clear catalysts for H2 2025

Management expects second-half revenue to exceed the first half as larger orders are delivered by year end. That is the core near-term catalyst. For investors, here are the markers to track:

• Revenue conversion from the $813k order book and pace of delivery in H2.
• Gross margin trajectory as automation and new services bed in.
• Operating cash flow and cash balance movements as fulfilment costs hit.
• Evidence of program-level, recurring engagements – and mix shift towards corporates.
• Adoption of newly launched products (Competitive Intelligence Report, Invention Validator) by additional clients.

My take

This reads like a classic first full post-IPO half: lots of groundwork, brand building and pipeline accumulation, but modest recognised revenue. The international wins and prepaid orders suggest the demand is real. Now it needs to show up in the income line.

If GenIP can execute on deliveries in H2 and demonstrate a step-up in both revenue and margin, the platform story gets more credible. Until then, it remains an early-stage, “show me” proposition with a healthy cash cushion and a growing global footprint.